Peer-reviewed veterinary case report
Blood cell problems in dogs with mast cell tumors on chemo
By Stiborova, K et al.·Published in The Journal of small animal practice·2019·Department of Small Animal Clinical Science, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Haematologic toxicity in dogs with mast cell tumours treated with vinblastine/prednisolone chemotherapy with/without radiotherapy.
- Species:
- dog
Plain-English summary
A group of dogs with mast cell tumors received a combination of chemotherapy (vinblastine and prednisolone) and radiation therapy after their tumors were surgically removed. The study found that adding radiation did not increase the risk of serious blood cell problems compared to dogs that only received chemotherapy. Both groups had similar rates of neutropenia, a condition where white blood cells are low. This means that treating dogs with mast cell tumors using both radiation and chemotherapy can be done safely without raising the risk of harmful side effects.
People also search for: dog mast cell tumor treatment · vinblastine side effects in dogs · radiation therapy for dogs with cancer
Abstract
OBJECTIVES: To determine whether dogs with surgically excised mast cell tumours receiving a vinblastine/prednisolone chemotherapy protocol in combination with radiation therapy are at greater risk of myelosuppression than patients receiving the chemotherapy protocol alone. MATERIALS AND METHODS: Retrospective study of clinical records of dogs with mast cell tumours that, subsequent to surgical excision, had received combination vinblasine/prednisolone chemotherapy. Dogs were assigned to two groups: those treated with adjunctive radiotherapy and vinblastine/prednisolone (RT group) and those treated with surgery followed by vinblastine/prednisolone alone (control group). Haematology results were compared between groups. RESULTS: Forty-three cases and 43 controls of similar breed, age and bodyweight were included. Concurrent radiation and vinblastine chemotherapy did not appear to increase the risk of neutropenia, which was observed in 18.6 and 23.2% of cases in the RT and control groups, respectively. CLINICAL SIGNIFICANCE: Radiation and vinblastine chemotherapy can be safely combined in dogs with mast cell tumours without increasing the risk of clinically important myelosuppression.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/31245847/